496 related articles for article (PubMed ID: 17419741)
1. Limited usefulness of CA125 measurement in the management of Hodgkin's and non-Hodgkin's lymphoma.
Bonnet C; Beguin Y; Fassotte MF; Seidel L; Luyckx F; Fillet G
Eur J Haematol; 2007 May; 78(5):399-404. PubMed ID: 17419741
[TBL] [Abstract][Full Text] [Related]
2. Serum CA 125 is of clinical value in the staging and follow-up of patients with non-Hodgkin's lymphoma: correlation with tumor parameters and disease activity.
Lazzarino M; Orlandi E; Klersy C; Astori C; Brusamolino E; Corso A; Bellio L; Gargantini L; Morra E; Bernasconi C
Cancer; 1998 Feb; 82(3):576-82. PubMed ID: 9452277
[TBL] [Abstract][Full Text] [Related]
3. Clinical relevance of soluble HLA-I and beta2-microglobulin levels in non-Hodgkin's lymphoma and Hodgkin's disease.
Albitar M; Vose JM; Johnson MM; Do KA; Day A; Jilani I; Kantarjian H; Keating M; O'Brien SM; Verstovsek S; Armitage JO; Giles FJ
Leuk Res; 2007 Feb; 31(2):139-45. PubMed ID: 16545870
[TBL] [Abstract][Full Text] [Related]
4. Serum level of intercellular adhesion molecule-1 in children with malignant lymphoma.
Abdelrazik N; Fouda M; Zaghloul MH; Abbas D
Med Princ Pract; 2008; 17(3):233-8. PubMed ID: 18408393
[TBL] [Abstract][Full Text] [Related]
5. Serum interleukin 6 levels are elevated in lymphoma patients and correlate with survival in advanced Hodgkin's disease and with B symptoms.
Kurzrock R; Redman J; Cabanillas F; Jones D; Rothberg J; Talpaz M
Cancer Res; 1993 May; 53(9):2118-22. PubMed ID: 8481913
[TBL] [Abstract][Full Text] [Related]
6. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma.
Bairey O; Blickstein D; Monselise Y; Lahav J; Stark P; Prokocimer M; Nativ HM; Kirgner I; Pazgal I; Shaklai M
Eur J Haematol; 2006 May; 76(5):384-91. PubMed ID: 16466368
[TBL] [Abstract][Full Text] [Related]
7. Hodgkin's and non-Hodgkin's lymphoma of the head and neck.
Urquhart A; Berg R
Laryngoscope; 2001 Sep; 111(9):1565-9. PubMed ID: 11568605
[TBL] [Abstract][Full Text] [Related]
8. The prognostic significance of beta(2)-microglobulin in patients with Hodgkin's lymphoma.
Vassilakopoulos TP; Nadali G; Angelopoulou MK; Siakantaris MP; Dimopoulou MN; Kontopidou FN; Karkantaris C; Kokoris SI; Kyrtsonis MC; Tsaftaridis P; Pizzolo G; Pangalis GA
Haematologica; 2002 Jul; 87(7):701-8; discussion 708. PubMed ID: 12091120
[TBL] [Abstract][Full Text] [Related]
9. [Importance of determination of serum beta-2-microglobulin levels in patients with Hodgkin's lymphoma].
Raida L; Papajík T; Hlusí A; Faber E; Urbanová R; Heczko M; Jancíková M; Zapletalová J; Komenda S; Indrák K
Vnitr Lek; 2002 Feb; 48(2):91-5. PubMed ID: 11949228
[TBL] [Abstract][Full Text] [Related]
10. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
11. Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma.
Moser EC; Kluin-Nelemans HC; Carde P; Meerwaldt JH; Tirelli U; Aleman BM; Baars J; Thomas J; van Glabbeke M; Noordijk EM
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1168-77. PubMed ID: 16887289
[TBL] [Abstract][Full Text] [Related]
12. [Detection of soluble interleukin-2 receptor in the serum of patients with non-Hodgkin's lymphoma].
Pérez Encinas M; Bello JL; Bendaña A; Rabuñal MJ; González S; Abuín I; Noya M; Cadarso C
Med Clin (Barc); 1998 Jul; 111(5):161-7. PubMed ID: 9732831
[TBL] [Abstract][Full Text] [Related]
13. Validation of the international prognostic index in working formulation group A low-grade non-Hodgkin's lymphoma: retrospective analysis of 137 patients from the Gruppo Italiano per lo Studio dei Linfomi registry.
Stelitano C; Baldini L; Pieresca C; Callea V; Angrilli F; Clò V; Partesotti G; Merli F; Cavanna L; Morabito F; Federico M; Brugiatelli M; Silingardi V
Haematologica; 2000 Feb; 85(2):154-9. PubMed ID: 10681722
[TBL] [Abstract][Full Text] [Related]
14. Serum CA125: a tumor marker for monitoring response to treatment and follow-up in patients with non-Hodgkin's lymphoma.
Zidan J; Hussein O; Basher W; Zohar S
Oncologist; 2004; 9(4):417-21. PubMed ID: 15266095
[TBL] [Abstract][Full Text] [Related]
15. Profiles and prognostic values of serum LDH isoenzymes in patients with haematopoietic malignancies.
Bouafia F; Drai J; Bienvenu J; Thieblemont C; Espinouse D; Salles G; Coiffier B
Bull Cancer; 2004; 91(7-8):E229-40. PubMed ID: 15381461
[TBL] [Abstract][Full Text] [Related]
16. Prevalence, clinical pattern, and outcome of CNS involvement in childhood and adolescent non-Hodgkin's lymphoma differ by non-Hodgkin's lymphoma subtype: a Berlin-Frankfurt-Munster Group Report.
Salzburg J; Burkhardt B; Zimmermann M; Wachowski O; Woessmann W; Oschlies I; Klapper W; Wacker HH; Ludwig WD; Niggli F; Mann G; Gadner H; Riehm H; Schrappe M; Reiter A
J Clin Oncol; 2007 Sep; 25(25):3915-22. PubMed ID: 17761975
[TBL] [Abstract][Full Text] [Related]
17. [Non-Hodgkin's lymphoma: clinical symptoms, therapy and prognosis in 37 patients].
Skunca Z; Gverić-Krecak V; Dominis M; Planinc-Peraica A; Jaksić B
Acta Med Croatica; 2003; 57(4):261-7. PubMed ID: 14639859
[TBL] [Abstract][Full Text] [Related]
18. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
[TBL] [Abstract][Full Text] [Related]
19. Early-mid treatment C-reactive protein level is a prognostic factor in aggressive non-Hodgkin's lymphoma.
Herishanu Y; Perry C; Braunstein R; Metser U; Goor O; Rogowski O; Berliner S; Polliack A; Naparstek E
Eur J Haematol; 2007 Aug; 79(2):150-4. PubMed ID: 17635239
[TBL] [Abstract][Full Text] [Related]
20. [Prognostic value of beta-2-microglobulin in Hodgkin disease in young adults].
Fleury J; Tortochaux J; Legros M; Cure H; Kwiatkowski F; Ferrière JP; Travade P; Dionet C; Gaillard G; Chassagne J
Bull Cancer; 1994 Jul; 81(7):625-31. PubMed ID: 7742606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
